Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial Infarction
Iocyte AMI-3 Trial to assess effectiveness and safety of FDY-5301 in improving outcomes for anterior STEMI patients undergoing primary PCI
United States Jo Anne Goldman Deepakl Bhatt Stephena Hill Steering Committee Minneapolis Heart Institute Foundation In
Source: dicardiology.com